Private Market View

Eradivir

West Lafayette, IN · Founded 2020 · Privately Held (backing)

Last price · $/share
—
Implied valuation
$113.0M
Total raised
$30.1M
Last round
—

Key facts

  • Eradivir’s last known valuation is $113.0M (Jul 2025).
  • It has raised $30.1M; the latest was Later Stage VC ($10.0M) in Jul 2025.
  • Notable investors include US National Science Foundation, Biomedical Advanced Research and Development Authority, National Science Foundation Innovation Corps Program, Ollin Ventures, Park City Angels — 9 tracked in total.
  • 1 investment vehicle was formed to buy Eradivir shares in the last 12 months, reporting $283K sold to 7 investors, per SEC Form D filings.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 9 names
  • ·Watchlist + deal alerts for Eradivir
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Eradivir are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Secondary demand: investment vehicles

from SEC Form D filings

In the last 12 months, 1 investment vehicle were formed to buy Eradivir shares, reporting $283K sold to 7 investors. Most recent filing Jun 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

The vehicle list — each sponsor, filing date, amount sold and investor count — is a Pro table. Unlock the 1 vehicle →
Companies with the most vehicle activity →

About Eradivir

Developer of a novel bispecific immunotherapy platform designed for patients' immune systems to kill both viruses and virus-infected cells. The company offers ligands with high specificity and avidity for a unique domain of the spike protein found on most coronaviruses, including COVID-19, enabling the medical industry to eliminate all free virus and virus-infected cells, even in late-stage infections.

Sector
Healthcare
HQ
West Lafayette, IN, United States
Founded
2020
Employees
23
Ownership
Privately Held (backing)
PA Mark — not yet priced

Eradivir doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Eradivir shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Eradivir in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.